Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
35 participants
INTERVENTIONAL
2022-08-15
2023-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
NCT00829296
Autonomic Nervous System and Nitric Oxide Interactions
NCT01137253
Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function
NCT01056718
Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients
NCT01502787
Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure
NCT02391142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
spontaneous recovery
Spontaneous recovery
Muscle relaxation
Rocuronium will be used to induce partial paralysis
reversal with sugammadex 2 mg/kg
reversal with sugammadex 2 mg/kg
Muscle relaxation
Rocuronium will be used to induce partial paralysis
Reversal
Sugamamdex will be used to reverse muscle relaxation
reversal with sugammadex 4 mg/kg
reversal with sugammadex 4 mg/kg
Muscle relaxation
Rocuronium will be used to induce partial paralysis
Reversal
Sugamamdex will be used to reverse muscle relaxation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Muscle relaxation
Rocuronium will be used to induce partial paralysis
Reversal
Sugamamdex will be used to reverse muscle relaxation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known or suspected neuromuscular disorders impairing neuromuscular function;
* Allergies to muscle relaxants, anesthetics or narcotics;
* A (family) history of malignant hyperthermia or any other muscle disease;
* Any neurological or psychiatric illness (including a history of anxiety).
* ASA class 3 or higher
* Gastro-oesophageal regurgitation
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leiden University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Martijn Boon
MD PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden Medical University
Leiden, South Holland, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P21.083
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.